Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Noelia Jáñez Martínez, Bent Ejlertsen et al.|The Lancet Oncology|2017

Cited by 594